Hormone replacement therapy in gynecological cancer survivors

Critical Reviews in Oncology/Hematology

Volumn 27, Issue 1, 1998, Pages 1-10

  Pecorelli, Sergio ^a   Fallo, Luca ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TAMOXIFEN;

BREAST CANCER; CANCER RISK; CHORIOCARCINOMA; CLINICAL TRIAL; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; OVARY CANCER; REVIEW; SARCOMA; UTERINE CERVIX CANCER; VAGINA CARCINOMA; VULVA CARCINOMA;

EID: 0031747786     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)10032-4     Document Type: Article

References (86)

1. [1] Cummings SR, Kelsey JL, Nevitt NC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1986;7:178-208.
2. [2] Stempfer MJ, Colditz GA. ERT and coronary heart disease: quantitative assessment of the epidemiologic evidence. Prev Med 1991;273:47-63.
3. [3] Schairer C, Adami HO, Hoover R, Persson I. Cause-specific mortality in women receiving HRT. Epidemiology 1997;8(1):59-65.
4. [4] Wren BG. Hormonal therapy following female genital tract cancer. Int J Gynecol Cancer 1994;4:217-24.
5. [5] Cullen KJ, Lippman ME. Estrogen regulation of protein synthesis and cell growth in human breast cancer. Vitam Horm 1989;45:127-72.
6. [6] Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 1987;8:29-43.
7. [7] Osborne CK, Arteaga CL. Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat 1990;15:3-11.
8. [8] Lerner LJ, Jordan VC. Development of anti-oestrogens and their use in breast cancer: eight cain memorial award lecture. Cancer Res 1990;50:4177-89.
9. [9] Haddow A, Watkinson JM, Petterson E. Influence of synthetic oestrogens on advanced malignant disease. Br Med J 1944;2:393-8.
10. [10] Rose C, Mouridsen HT. Endocrine management of advanced breast cancer. Horm Res 1989;32 (Suppl 1):189-97.
11. [11] Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
12. [12] Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301.
13. [13] Mauvais-Jarvis P, Kuttenn F, Gompel A. Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat 1986;8(3):179-88.
14. [14] Wren BG. Hormonal replacement therapy and breast cancer. Eur Menopause J 1995;2(4):13-9.
15. [15] Musgrave EA, Lee CSL, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing TGF-α, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991;11:5032-43.
16. [16] Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988;24(1):29-43.
17. [17] Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiol Rev 1993;15(1):98-107.
18. [18] Anderson TJ, Battersby S. The involvement of oestrogen in the development and function of the normal breast: histological evidence. Proceedings of R Soc Edin (Beck JS, editor) 1989; 23-32.
19. [19] Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about HRT in post-menopausal women. J Am Med Assoc 1997;277:1140-7.
20. [20] Ribeiro G, Jones DA, Jones M. Carcinoma of the breast associated with pregnancy. Br J Surg 1986;73:607-9.
21. [21] King RM, Welch JS, Martin JK Jr. Carcinoma of the breast associated with pregnancy. Surg Gynecol Obstet 1985;160:228-32.
22. [22] Mignot L, Morvan F, Berdah J, et al. Grossesses apres cancer du sein traite. Resultats d'une etude cas-temoins. Presse Med 1986;15:1961-4.
23. [23] Cooper DR, Butterfield J. Pregnancy subsequent to mastectomy for cancer of the breast. Ann Surg 1970;171:429-33.
24. [24] Clark RM, Reid JM. Carcinoma of the breast in pregnancy and lactation. Int J Radiat Oncol Biol Phys 1978;4:693.
25. [25] Rosner D, Lane W. Oral contraceptives use has no adverse effect on the prognosis of breast cancer. Cancer 1986;57:591-6.
26. [26] Ravdin RG, Lewison EF, Slack NH, Dao TL, Gardner B, State D, Fisher B. Results of clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet 1970;131:1055-64.
27. [27] Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. New Engl J Med 1989;321:293-7.
28. [28] Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;130:221-8.
29. [29] Armstrong BK. Oestrogen therapy after the menopause: boon or bane? Med J Aust 1988;148:213-4.
30. [30] Dupont VD, Page DL. Menopausal ERT and breast cancer. Arch Intern Med 1991;151:67-72.
31. [31] Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of ERT on the risk of breast cancer. J Am Med Assoc 1991;265:1985-90.
32. [32] Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Fargas R. Menopausal HRT and breast cancer: a meta-analysis. Obstet Gynecol 1992;79:286-94.
33. [33] Colditz GA, Egan KM, Stampfer MJ. HRT and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-80.
34. [34] Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med 1992;117(12):1016-37.
35. [35] Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and risk of breast cancer in post-menopausal women. New Engl J Med 1995;335:1589-93.
36. [36] Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of ERT. Arch Intern Med 1991;151:75-8.
37. [37] Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of HRT: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
38. [38] Criqui MH, Suarez L, Barrett-Connor E, McPhillips JW, Garbard C. Post-menopausal estrogen use and mortality. Am J Epidemiol 1988;128:606-14.
39. [39] Grodstein F, Stempfer MJ, Colditz GA, et al. Post-menopausal hormone therapy and mortality. New Engl J Med 1997;336:1769-75.
40. [40] Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin HRT in relation to risk of breast cancer in middle-aged women. J Am Med Assoc 1995;274:137-42.
41. [41] Newcomb PA, Longnecker MP, Storer BE, et al. Long-term HRT and risk of breast cancer in post-menopausal women. Am J Epidemiol 1995;142(8):788-95.
42. [42] The PEPI Trial Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. J Am Med Assoc 1995;273:199-208.
43. [43] Wren BG. HRT and breast cancer. Eur Menopause J 1995;2(4):13-9.
44. [44] DiSaia PJ. Hormone-replacement therapy in patients with breast cancer: a re-appraisal. Cancer 1993;71:1490-500.
45. [45] Marchant DJ. Estrogen-replacement therapy after breast cancer: risks versus benefits. Cancer 1993;71:2169-76.
46. [46] Lobo RA. HRT: oestrogen replacement after treatment for breast cancer? Lancet 1993;341:1313-4.
47. [47] DiSaia PJ, Odicino F, Grosen EA, Cowan B, Pecorelli S, Wile AG. HRT in breast cancer (letter). Lancet 1993;342:232.
48. [48] Di Saia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. HRT in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996;174:494-8.
49. [49] Powles C. HRT after breast cancer (letter). Lancet 1993;342:60-1.
50. [50] Stoll BA, Parbhoo S. Treatment of menopausal symptoms in breast cancer patients. Lancet 1988;i:1278-9.
51. [51] Wile AG, Opfell RW, Margileth DA. Hormone replacement in previously treated breast cancer patients. Am J Surg 1993;165:372-5.
52. [52] Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995;2:67-72.
53. [53] Vassilopoulou-Sellin R, Theriault R, Klein MJ. ERT in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997;65(1):89-93.
54. [54] Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, De Mets DL. Effects of tamoxifen therapy on lipid and lipoprotein levels in post-menopausal patients with nodenegative breast cancer. J Natl Cancer Inst 1990;82:1327-32.
55. [55] Killacke MA, Halkes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients, receiving anti-estrogens. Cancer Treat Rep 1985;69:237-8.
56. [56] Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson BL. ERT in the patient treated for endometrial cancer. Obstet Gynecol 1986;647:326-30.
57. [57] Lee RB, Burke TW, Park RC. ERT following treatment for stage I endometrial cancer. Gynaecol Oncol 1990;36:189-91.
58. [58] Baker DD. ERT in patients with previous endometrial carcinoma. Comp Ther 1990;16:28-35.
59. [59] Bryant GW. Administration of estrogen to patients with a previous diagnosis of endometrial adenocarcinoma. South Med J 1990;83:725-6.
60. [60] ACOG Committee Opinion, no. 80, February 1990.
61. [61] Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987;26:169-77.
62. [62] Pejovic-Lenfant MH. Risque carcinologique des traitements hormonaux substitutifs de la menopause. J Gynec Obstet Biol Reprod 1989;18:153-6.
63. [63] Polychronopoulou A, Tzonou A, Hsieh CC, Kaprinis G, Rebelakos A, Toupadaki N, Trichopoulos D. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993;55(3):402-7.
64. [64] Parazzini F, La Vecchia C, Negri E, Villa A. ERT and ovarian cancer risk. Int J Cancer 1994;57:135-6.
65. [65] Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath CW Jr. ERT and fatal ovarian cancer. Am J Epidemiol 1995;141:828-35.
66. [66] Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136(10):1184-203.
67. [67] Schwartz PE, Naftolin F. Hormone therapy. In: Berek JS, Hacker NF, editors. Practical Gynecologic Oncology. Baltimore, MD: Williams & Wilkins, 1994:613-36.
68. [68] Rendina GM, Donadio C, Giovannini M. Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma. Eur J Gynaecol Oncol 1982;3:241-6.
69. [69] Colombo N, Chiari S, Maggioni A, Bocciolone L, Torri V, Mangioni C. Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy. Gynecol Oncol 1994;55:47-51.
70. [70] Fishman DA, Schwartz PE. Current approaches to diagnosis and treatment of ovarian germ cell malignancies. Curr Opinion Obstet Gynecol 1994;6:98-104.
71. [71] Eeles RA, Tan S, Wiltshaw E, et al. HRT and survival after surgery for ovarian cancer. Br Med J 1991;302:259-62.
72. [72] Ngan HY, Wong LC, Ma HK. reproductive performance of patients with gestational trophoblastic disease in Hong Kong. Acta Obstet Gynecol Scand 1988;67:11-4.
73. [73] Ayhan A, Ergeneli MH, Yuce K, Yappar EG, Kisnisci AH. Pregnancy after chemotherapy for gestational trophoblastic disease. J Reprod Med 1990;35:522-4.
74. [74] DeMola L Jr, Goldfarb JM. Reproductive performance of patients after gestational trophoblastic disease. Semin Oncol 1995;22:193-7.
75. [75] Cantin J, McNeer GP. The effect of pregnancy on the clinical course of sarcoma of the soft somatic tissues. Surg Gynecol Obstet 1967;125:28-32.
76. [76] Chaudhuri PK, Walker MJ, Beattie CW, Das Gupta TK. Distribution of steroid hormone receptors in human soft tissue sarcomas. Surgery 1981;90:149-52.
77. [77] Horowitz K, Rutherford T, Schwartz PE. HRT in women with sarcomas. CME J Gynecol Oncol 1996;1:23-9.
78. [78] Fox H. HRT and sarcoma. CME J Gynecol Oncol 1996;1:30-1.
79. [79] Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol 1990;39(3):364-7.
80. [80] Vassilopolou-Sellin R, Theriault RL. Randomized prospective trial of ERT in women with a history of breast cancer. Monogr Natl Cancer Inst 1994;16:153-9.
81. [81] Strickland DM, Gambrell RD, Butzin CA, Strickland K. The relationship between breast cancer survival and prior post-menopausal estrogen use. Obstet Gynecol 1992;80:400-4.
82. [82] Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND. Carcinoma of the breast in post-menopausal hormone user and non-user controls. J Am Coll Surg 1994;178:167-70.
83. [83] Bonnier P, Romain S, Giacaione PL, Laffargue F, Martin PM, Piana L. Clinical and biological prognostic factors in breast cancer diagnosed during post-menopausal HRT. Obstet Gynecol 1995;85:11-7.
84. [84] Newcomb PA, Storer BE. Post-menopausal hormone use and risk of large bowel cancer. J Natl Cancer Inst 1995;87:1067-71.
85. [85] Harlap S. The benefits and risks of HRT: an epidemiologic overview. Am J Obstet Gynecol 1992;166:1986-92.
86. [86] Ross RK, Pike MC, Henderson BE, Mack TM, Lobo RA. Stroke prevention and ERT (letter). Lancet 1989;1(8636):505.